Biotech deals hit $106B in 2026 despite Iran war inflation, driven by patent cliffs and China scouting. Industry adapts with strategic M&A.
Novo Nordisk launches Wegovy oral weight-loss drug in the UAE, its first market outside the US, signaling global expansion amid rising competition from Eli Lilly's Foundayo.
Novo Nordisk eyes Denmark, UK, and Germany for Wegovy pill launch, targeting global weight loss market beyond US dominance.
Bayer posts 9% operating profit jump in Q1, beating expectations. Analysis of how this contrasts with Germany's broader economic slowdown.
Novo Nordisk raises 2026 outlook as Wegovy captures 65% of new US prescriptions, while Pandora faces tariff and silver price pressures.